Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Arena Pharma and Everest Medicines Enter into Agreement 12
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 13
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 14
Abic Marketing Enters into Agreement with Arena Pharma 15
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 16
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 18
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 19
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 20
Licensing Agreements 21
Outpost Medicine Enters into Licensing Agreement with Arena Pharma 21
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 22
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 24
Equity Offering 25
Arena Pharma Prices Public Offering of Shares for USD352.8 Million 25
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 27
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 29
Arena Pharma Raises USD3.2 Million in Public Offering of Shares 31
Arena Pharma to Raise Funds through Public Offering of Shares 32
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 33
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 34
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 36
Asset Transactions 38
Siegfried to Acquire Zofingen Manufacturing Facility from Arena Pharma 38
Arena Pharmaceuticals Inc – Key Competitors 39
Arena Pharmaceuticals Inc – Key Employees 40
Arena Pharmaceuticals Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Aug 06, 2018: Arena Pharmaceuticals provides corporate update and reports second quarter 2018 financial results 42
May 08, 2018: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2018 Financial Results 44
Mar 14, 2018: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results 45
Nov 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2017 Financial Results 47
Aug 07, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2017 Financial Results 48
May 09, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2017 Financial Results 50
Mar 14, 2017: Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 51
Corporate Communications 53
Jul 10, 2018: Arena Pharmaceuticals Names Life Sciences Industry Veteran Kieran T. Gallahue to Board of Directors 53
Feb 16, 2018: Arena Pharmaceuticals Announces Board Changes 54
Jun 14, 2017: Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors 55
Mar 20, 2017: Arena Pharmaceuticals Appoints Dr. Preston Klassen, M.D., M.H.S. as Executive Vice President, Research and Development and Chief Medical Officer 56
Feb 14, 2017: Arena Pharmaceuticals Appoints Three New Members to Board of Directors 57
Product News 58
02/09/2017: Arena Pharmaceuticals Announces Three Upcoming Presentations at the 12th Congress of European Crohn’s and Colitis Organisation – Inflammatory Bowel Diseases 2017 58
01/22/2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City 59
Clinical Trials 61
Oct 08, 2018: Arena Pharmaceuticals presented phase 2 clinical data for Etrasimod in ulcerative colitis at the American College of Gastroenterology Annual Meeting 61
Oct 02, 2018: Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension 62
Sep 24, 2018: Arena Pharmaceuticals reports positive phase 2a results for Olorinab in patients with abdominal pain associated with Crohn’s disease 63
Sep 17, 2018: Arena Pharmaceuticals Presents Preclinical Data for Olorinab at International Association for the Study of Pain World Congress 64
Aug 28, 2018: Arena Pharmaceuticals presented phase 1 clinical data for Ralinepag in pulmonary arterial hypertension at the European Society of Cardiology 65
May 21, 2018: Arena Pharmaceuticals Announces Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference 66
Apr 12, 2018: Arena Pharmaceuticals Announces Phase 2 Data Presentation for Ralinepag in Pulmonary Arterial Hypertension at the International Society for Heart and Lung Transplantation Annual Meeting 67
Mar 19, 2018: Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis 68
Mar 01, 2018: Arena Pharmaceuticals to Present Phase 1 and Preclinical Data on APD371 in Development for Treatment of Pain Associated with Crohn’s Disease at American Pain Society Annual Scientific Summit 69
Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis 70
Oct 19, 2017: Arena Pharmaceuticals Announces Late Breaking Presentation of Positive Phase 2 Results with Ralinepag in Patients with Pulmonary Arterial Hypertension at the American College of Chest Physicians 2017 Annual Meeting 71
Sep 06, 2017: Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at International Congress of the European Respiratory Society 72
Aug 22, 2017: Arena Pharmaceuticals to Present Additional Pre-Clinical Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at European Society of Cardiology Congress 73
Jul 10, 2017: Arena Pharmaceuticals Reports Positive Topline Phase 2 Results for Ralinepag in Patients with Pulmonary Arterial Hypertension 74
Jun 29, 2017: Arena Pharmaceuticals Completes Trial Comparing Once-Daily, Extended Release Formulation of Ralinepag with Twice-Daily, Immediate Release Formulation in Normal Healthy Volunteers 75
May 18, 2017: Arena Pharmaceuticals to Host Key Opinion Leader Event on Pulmonary Arterial Hypertension (PAH) on May 25 in New York City 76
May 16, 2017: Arena Pharmaceuticals to Present Phase 1 Data on Ralinepag for Treatment of Pulmonary Arterial Hypertension at the American Thoracic Society 2017 International Conference 77
Apr 17, 2017: Arena Pharmaceuticals Announces Multiple Presentations at ASPET 2017 at Experimental Biology 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arena Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arena Pharma and Everest Medicines Enter into Agreement 12
Boehringer Ingelheim Enters into Research Agreement with Arena Pharma 13
Arena Pharma Enters into Co-Development and Marketing Agreement with Roivant 14
Abic Marketing Enters into Agreement with Arena Pharma 15
Eisai Amends its Co-Marketing Agreement with Arena Pharma for Belviq 16
Arena Pharma Enters Into Co-Marketing Agreement With CY Biotech For Lorcaserin 18
Arena Pharma Enters Into Co-Marketing Agreement With Ildong Pharma For Belviq 19
Arena Pharma Expands Co-Marketing Agreement With Eisai For Lorcaserin 20
Outpost Medicine Enters into Licensing Agreement with Arena Pharma 21
Arena Pharma Enters Into Licensing And Co-Development Agreement With Ildong Pharma For Temanogrel 22
Suzhou Connect Biopharma Enters Into Licensing Agreement With Arena Pharma For Inflammatory Compounds 24
Arena Pharma Prices Public Offering of Shares for USD352.8 Million 25
Arena Pharma Raises USD172.5 Million in Public Offering of Shares 27
Arena Pharma Raises USD79.4 Million in Public Offering of Shares 29
Arena Pharma Raises USD3.2 Million in Public Offering of Shares 31
Arena Pharma to Raise Funds through Public Offering of Shares 32
Arena Pharma Completes Public Offering Of Common Stock For US$70 Million 33
Arena Pharma Completes Private Placement Of Common Stock For US$16.5 Million 34
Arena Pharma Completes Private Placement Of Series D Preferred Stock For US$16.5 Million 36
Siegfried to Acquire Zofingen Manufacturing Facility from Arena Pharma 38
Arena Pharmaceuticals Inc, Key Competitors 39
Arena Pharmaceuticals Inc, Key Employees 40
Arena Pharmaceuticals Inc, Other Locations 41
Arena Pharmaceuticals Inc, Subsidiaries 41
List of Figures
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arena Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9